Skip to content

Why Is Sarepta Therapeutics’ Orphan Drug Eteplirsen In The News Again (December 7, 2012) ?

December 7, 2012

       Sarepta Therapeutics announces on December 7, 2012, that there is a “continuation of benefit on the Walking Test through 62 weeks in Phase IIb Open-Label Extension Study of Eteplirsen in Duchenne Muscular Dtstriohy (DMD)”. 

        Jerry R. Mendell, M.D., the Principal Investigator of the trial, is to give an oral presentation of this 62-week trial data, at the European Neuromuscular Centre (ENMC) Workshop today, December 7, 2012 at 4:20 p.m. UTC/GMT +1 hours/10:20 a.m. EDT. The presentation is to be posted on the Sarepta Therapeutics’ after the session is completed. 

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: